CA2391129A1 - Transduction de cellules souches hematopoietiques par vecteur de lentivirus - Google Patents

Transduction de cellules souches hematopoietiques par vecteur de lentivirus Download PDF

Info

Publication number
CA2391129A1
CA2391129A1 CA002391129A CA2391129A CA2391129A1 CA 2391129 A1 CA2391129 A1 CA 2391129A1 CA 002391129 A CA002391129 A CA 002391129A CA 2391129 A CA2391129 A CA 2391129A CA 2391129 A1 CA2391129 A1 CA 2391129A1
Authority
CA
Canada
Prior art keywords
vector
hematopoietic stem
cells
stem cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002391129A
Other languages
English (en)
Inventor
Wen Yong Chen
Xiaoyun Wu
John C. Kappes
Tim M. Townes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2391129A1 publication Critical patent/CA2391129A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des procédés de préparation et d'utilisation de ces compositions en rapport avec la transduction de cellules souches hématopoïétiques. Elle concerne des vecteurs de lentivirus capables d'effectuer la transduction de populations purifiées de cellules souches hématopoïétiques. On peut mettre en application ces compositions et ces procédés afin de traiter des maladies présentant des troubles sanguins, telles que la drépanocytose ou la thalassémie.
CA002391129A 1999-11-10 2000-11-10 Transduction de cellules souches hematopoietiques par vecteur de lentivirus Abandoned CA2391129A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16462599P 1999-11-10 1999-11-10
US60/164,625 1999-11-10
PCT/US2000/030882 WO2001034843A1 (fr) 1999-11-10 2000-11-10 Transduction de cellules souches hematopoietiques par vecteur de lentivirus

Publications (1)

Publication Number Publication Date
CA2391129A1 true CA2391129A1 (fr) 2001-05-17

Family

ID=22595350

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002391129A Abandoned CA2391129A1 (fr) 1999-11-10 2000-11-10 Transduction de cellules souches hematopoietiques par vecteur de lentivirus

Country Status (5)

Country Link
EP (1) EP1230394A4 (fr)
JP (1) JP2003517301A (fr)
AU (1) AU784988B2 (fr)
CA (1) CA2391129A1 (fr)
WO (1) WO2001034843A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
IL160132A0 (en) 2001-08-02 2004-06-20 Inst Clayton De La Rech Methods and compositions relating to improved lentiviral vector production systems
CA2915676C (fr) 2001-10-02 2017-06-06 Institut Clayton De La Recherche Vecteurs lentiviraux a expression reduite
US7566535B2 (en) 2002-03-07 2009-07-28 University Of Delaware Enhanced oligonucleotide-mediated nucleic acid sequence alteration
PL3214091T3 (pl) * 2010-12-09 2019-03-29 The Trustees Of The University Of Pennsylvania Zastosowanie komórek T modyfikowanych chimerycznymi receptorami antygenowymi do leczenia nowotworów
WO2012094193A2 (fr) * 2011-01-03 2012-07-12 Bluebird Bio, Inc. Procédés pour améliorer l'administration de cellules transduites avec un gène
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
US10653123B2 (en) 2014-05-27 2020-05-19 Dana-Farber Cancer Institute, Inc. Methods and compositions for perturbing gene expression in hematopoietic stem cell lineages in vivo
SG11201708191XA (en) 2015-04-08 2017-11-29 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
TWI650419B (zh) * 2016-09-13 2019-02-11 中央研究院 藉移植增加壽命及/或治療細胞增殖疾病之方法
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
WO2019009979A1 (fr) 2017-07-06 2019-01-10 The Medical College Of Wisconsin, Inc. Nouvelle stratégie d'enrichissement in vitro et in vivo ciblant les lymphocytes dérivés de csh transduites par un vecteur pour la thérapie de troubles

Also Published As

Publication number Publication date
EP1230394A4 (fr) 2002-12-18
AU1594401A (en) 2001-06-06
WO2001034843A1 (fr) 2001-05-17
EP1230394A1 (fr) 2002-08-14
JP2003517301A (ja) 2003-05-27
AU784988B2 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
Hanawa et al. Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus–based lentiviral vector system
Moritz et al. Human cord blood cells as targets for gene transfer: potential use in genetic therapies of severe combined immunodeficiency disease.
KR101990068B1 (ko) 렌티바이러스 벡터의 안정한 제조
US8501464B2 (en) Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
EP2761010B1 (fr) Vecteurs de lentivirus pseudotypés avec des glycoprotéines d'enveloppe de baev mutees
Vassilopoulos et al. Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors
Nagano et al. Lentiviral vector transduction of male germ line stem cells in mice
US20090148425A1 (en) Therapeutic method for blood coagulation disorder
US20200347404A1 (en) Lentiviral vectors expressing foxp3 in hematopoietic stem cells to treat immune deficiencies and autoimmune diseases
AU784988B2 (en) Lentiviral vector transduction of hematopoietic stem cells
Chen et al. Lentiviral vector transduction of hematopoietic stem cells that mediate long-term reconstitution of lethally irradiated mice
JP2018519827A (ja) 逆配向のヒトユビキチンｃプロモーターを含むレトロウイルスベクター
Tahara-Hanaoka et al. Lentiviral vector–mediated transduction of murine CD34− hematopoietic stem cells
KR101891626B1 (ko) 렌티바이러스 벡터의 반-안정성 산물
Douglas et al. Efficient human immunodeficiency virus-based vector transduction of unstimulated human mobilized peripheral blood CD34+ cells in the SCID-hu Thy/Liv model of human T cell lymphopoiesis
Liu et al. Identification of parameters required for efficient lentiviral vector transduction and engraftment of human cord blood CD34+ NOD/SCID-repopulating cells
Pan et al. Prolonged adherence of human immunodeficiency virus-derived vector particles to hematopoietic target cells leads to secondary transduction in vitro and in vivo
WO2008136656A1 (fr) Procédés perfectionnés et moyens pour l'administration de gènes lentiviraux
US20220378937A1 (en) Lentiviral vectors in hematopoietic stem cells to treat x-linked chronic granulomatous disease
Derdouch et al. Reconstitution of the myeloid and lymphoid compartments after the transplantation of autologous and genetically modified CD34+ bone marrow cells, following gamma irradiation in cynomolgus macaques
CA3219359A1 (fr) Vecteurs lentiviraux et utilisations de ceux-ci
Mouly et al. CD4 regulation in human lymphoid non-T-cells: a role for the silencer element
EP2021484B1 (fr) Vecteurs d'expression comprenant le promoteur hs1 de l'oncogène vav1 et leurs utilisations pour la préparation de compositions pharmaceutiques destinées à une thérapie génique somatique

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead